RYTM
Rhythm Pharmaceuticals, Inc.
Stock
$92.83−0.58 (−0.62%)Close Oct 2, 2026
Balance sheet
| Line | Q2 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $331M | $389M | $321M | $276M | $333M | $295M | $173M | $292M | $252M | $148M | $11M | $35M |
| Inventory | $31M | $26M | $19M | $8.6M | $2.9M | $111K | — | — | — | — | — | — |
| Current assets | $427M | $467M | $374M | $308M | $354M | $308M | $182M | $302M | $259M | $151M | $11M | — |
| Intangible assets | $4.9M | $5.3M | $6.2M | $7.0M | $7.9M | $4.7M | — | — | — | — | — | — |
| Total assets | $437M | $480M | $392M | $333M | $382M | $330M | $187M | $309M | $260M | $152M | $12M | — |
| Current liabilities | $124M | $106M | $116M | $55M | $40M | $43M | $18M | $24M | $14M | $6.7M | $4.7M | — |
| Long-term debt | $93M | $101M | $108M | $106M | — | — | — | — | — | — | — | — |
| Total liabilities | $220M | $210M | $228M | $163M | $118M | $45M | $21M | $28M | $14M | $6.9M | $5.0M | — |
| Shareholders' equity | $103M | $139M | $22M | $170M | $264M | $284M | $167M | $281M | $246M | $145M | −$33M | −$8.0M |
| Shares outstanding | 68.9M | 68.3M | 63.2M | 60.1M | 56.7M | 50.3M | 50.2M | 44.1M | 34.4M | 27.3M | — | — |
| Current ratio | 3.45 | 4.41 | 3.24 | 5.58 | 8.90 | 7.10 | 10.10 | 12.38 | 19.05 | 22.42 | 2.36 | — |